scholarly journals Placental Protein 13 Administration to Pregnant Rats Lowers Blood Pressure and Augments Fetal Growth and Venous Remodeling

2015 ◽  
Vol 39 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Sveinbjorn Gizurarson ◽  
Elisabet Run Sigurdardottir ◽  
Hamutal Meiri ◽  
Berthold Huppertz ◽  
Marei Sammar ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Spontaneous Mutation ◽  
Blood Pressure Reduction ◽  
Subsequent Development ◽  
First Trimester ◽  
Hypotensive Effect ◽  
Carbohydrate Binding ◽  
Pregnant Rats ◽  
Beneficial Effects ◽  
Placental Protein

Reduced first-trimester concentrations of placental protein 13 (PP13) are associated with subsequent development of preeclampsia, a major pregnancy disorder. We previously showed that PP13 has a vasodilatory effect, reduces blood pressure and augments expansive remodeling of the uteroplacental vasculature in pregnant rats. In this study, slow-release osmotic pumps were implanted in gravid rats (on day 8) to provide 1 week of PP13 supplementation. Treatment was associated with a reversible blood pressure reduction that returned to normal on day 15. In addition, PP13 caused venous expansion that is larger in the venous branches closer to the placenta. Then, it increased placental and pup weights. Similar administration of a truncated PP13 variant (DelT221) that is unable to bind carbohydrates (a rare spontaneous mutation associated with a high frequency of severe early preeclampsia among Blacks in South Africa) produced a hypotensive effect similar to the full-length molecule, but without venous remodeling and increased placental and pup weights. These results indicate the importance of PP13 carbohydrate binding for inducing vascular remodeling and improving reproductive outcome. Future studies are needed to determine whether beneficial effects would be evident in animal models of preeclampsia or in women predisposed to the development of preeclampsia.

THE FALL OF BLOOD PRESSURE FOLLOWING INDUCTION OF DECIDUOMATA IN STEROID HYPERTENSIVE RATS RECEIVING PROGESTERONE

1968 ◽  
Vol 59 (2) ◽  
pp. 227-234 ◽  
Author(s):  
H. C. Moore ◽  
I. Cserhati ◽  
F. P. Biliczki
Keyword(s):  
Blood Pressure ◽  
Hypotensive Effect ◽  
Hypertensive Rats ◽  
Pregnant Rats ◽  
Hypertensive Rat ◽  
Equivalent Time ◽  
Metrial Gland ◽  
Blood Pressure Responses ◽  
A Minor ◽  
Maternal Decidua

ABSTRACT Experimental deciduomata and progesterone together lower the blood pressure in the steroid hypertensive rat from the 5th to 10th day of decidual growth i. e. from the 10th to 15th day of pseudopregnancy. This would suggest that the fall of blood pressure at an equivalent time of gestation in hypertensive pregnant rats could be due to the maternal decidua under the influence of progesterone. It is further considered that the metrial gland of the deciduoma is more likely to be responsible for the hypotensive effect and by comparison that the metrial gland is implicated in the hypotensive effect of pregnancy. Progesterone alone also exerts a minor hypotensive effect in those animals in which a nephrectomy forms part of the hypertension regimen and indicates one way in which a maternal renal factor could influence blood pressure responses in hypertensive pregnant rats.

Placental protein 13 (PP13) shows beneficial effects on the maternal vasculature in pregnant rats: Potential benefits in preeclampsia and IUGR

Placenta ◽  
2014 ◽  
Vol 35 (9) ◽  
pp. A85
Author(s):  
Sveinbjorn Gizurarson ◽  
Hamutal Meiri ◽  
Berthold Huppertz ◽  
Marei Sammar ◽  
George Osol
Keyword(s):  
Pregnant Rats ◽  
Beneficial Effects ◽  
Potential Benefits ◽  
Placental Protein

The effects of dietary nitrate on blood pressure and endothelial function: a review of human intervention studies

2013 ◽  
Vol 26 (2) ◽  
pp. 210-222 ◽  
Author(s):  
Ditte A. Hobbs ◽  
Trevor W. George ◽  
Julie A. Lovegrove
Keyword(s):  
Blood Pressure ◽  
Endothelial Function ◽  
Systolic Blood Pressure ◽  
Intervention Studies ◽  
Blood Pressure Reduction ◽  
Oral Bacteria ◽  
Human Intervention ◽  
Dietary Nitrate ◽  
Beneficial Effects ◽  
Healthy Humans

Evidence has accumulated in recent years that suggests that nitrate from the diet, particularly vegetables, is capable of producing bioactive NO in the vasculature, following bioconversion to nitrite by oral bacteria. The aim of the present review was to consider the current body of evidence for potential beneficial effects of dietary nitrate on blood pressure and endothelial function, with emphasis on evidence from acute and chronic human intervention studies. The studies to date suggest that dietary nitrate acutely lowers blood pressure in healthy humans. An inverse relationship was seen between dose of nitrate consumed and corresponding systolic blood pressure reduction, with doses of nitrate as low as 3 mmol of nitrate reducing systolic blood pressure by 3 mmHg. Moreover, the current studies provide some promising evidence on the beneficial effects of dietary nitrate on endothelial function.In vitrostudies suggest a number of potential mechanisms by which dietary nitrate and its sequential reduction to NO may reduce blood pressure and improve endothelial function, such as: acting as a substrate for endothelial NO synthase; increasing vasodilation; inhibiting mitochondrial reactive oxygen species production and platelet aggregation. In conclusion, the evidence for beneficial effects of dietary nitrate on blood pressure and endothelial function is promising. Further long-term randomised controlled human intervention studies assessing the potential effects of dietary nitrate on blood pressure and endothelial function are needed, particularly in individuals with hypertension and at risk of CVD.

scholarly journals Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Vasilios Papademetriou ◽  
Michael Doumas ◽  
Charles Faselis ◽  
Constantinos Tsioufis ◽  
Stella Douma ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Resistant Hypertension ◽  
Blood Pressure Reduction ◽  
Current Data ◽  
Pressure Reduction ◽  
Beneficial Effects ◽  
Carotid Baroreceptor ◽  
Complex Anatomy ◽  
Baroreceptor Stimulation ◽  
Carotid Baroreceptor Stimulation

Interventional activation of the carotid baroreflex has been an appealing idea for the management of resistant hypertension for several decades, yet its clinical application remained elusive and a goal for the future. It is only recently that the profound understanding of the complex anatomy and pathophysiology of the circuit, combined with the accumulation of relevant experimental and clinical data both in animals and in humans, has allowed the development of a more effective and well-promising approach. Indeed, current data support a sustained over a transient reduction of blood pressure through the resetting of baroreceptors, and technical deficits have been minimized with a subsequent recession of adverse events. In addition, clinical outcomes from the application of a new implantable device (Rheos) that induces carotid baroreceptor stimulation point towards a safe and effective blood pressure reduction, but longer experience is needed before its integration in the everyday clinical practice. While accumulating evidence indicates that carotid baroreceptor stimulation exerts its benefits beyond blood pressure reduction, further research is necessary to assess the spectrum of beneficial effects and evaluate potential hazards, before the extraction of secure conclusions.

scholarly journals Cardiorenal effects of newer antidiabetic agents

2020 ◽  
pp. 48-59
Author(s):  
Athanasia K. Papazafiropoulou ◽  
Elias Georgopoulos ◽  
Stavros Antonopoulos
Keyword(s):  
Blood Pressure ◽  
Cardiovascular System ◽  
Blood Pressure Reduction ◽  
Antidiabetic Agents ◽  
Mortality And Morbidity ◽  
Receptor Agonists ◽  
Beneficial Effects ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Optimal Blood Pressure

Chronic kidney disease is a major problem of public health and is associated with increased cardiovascular mortality and morbidity. Its treatment includes multifactorial intervention: optimal blood pressure and intensive glycaemic control. There are many studies – clinical and experimental – demonstrating that classic and newer antidiabetic agents delay the progression of diabetic nephropathy. Glucagon-like-peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporters-2 (SGLT-2) inhibitors have renoprotective action. Furthermore, these antidiabetic agents have beneficial effects to the cardiovascular system, including weight loss and blood pressure reduction. Large, randomized, placebo-controlled outcome trials have showed that SGLT-2 inhibitors and GLP-1 receptor agonists are able to reduce cardiovascular events. Therefore, the present review aims to summarize the existing data regarding the effect of newer antidiabetic agents on kidney function and cardiovascular system.

scholarly journals BENEFICIAL EFFECTS OF BLOOD PRESSURE REDUCTION ON AORTIC STIFFNESS AND CENTRAL HEMODYNAMICS IN PATIENTS WITH METABOLIC SYNDROME

2015 ◽  
Vol 65 (10) ◽  
pp. A1469
Author(s):  
Panagiota Pietri ◽  
Charalambos Vlachopoulos ◽  
Dimitris Terentes-Printzios ◽  
Nikolaos Ioakeimidis ◽  
Mahmoud Abdelrasoul ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Aortic Stiffness ◽  
Blood Pressure Reduction ◽  
Pressure Reduction ◽  
Central Hemodynamics ◽  
Beneficial Effects

scholarly journals COMPARATIVE STUDY ON THE BENEFICIAL EFFECTS OF TELMISARTAN AND OTHER ANTIHYPERTENSIVE AGENTS IN STROKE PATIENTS

2017 ◽  
Vol 9 (2) ◽  
pp. 99
Author(s):  
Anju Jose ◽  
Deepthi Wilson ◽  
Mintu George ◽  
Reshma K. Thomas ◽  
A. Justin
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Reduction ◽  
Antihypertensive Agents ◽  
Neurological Dysfunction ◽  
Stroke Recurrence ◽  
Stroke Treatment ◽  
Nihss Score ◽  
Beneficial Effects ◽  
Multiple Comparison Test ◽  
Term Basis

<p class="ParaAttribute0">Objective<strong>:</strong> To compare the beneficial effects of telmisartan with other anti-hypertensive agents during stroke with respect to improvement from neurological dysfunction.</p><p class="ParaAttribute0"><strong>Methods: </strong>A prospective observational study was performed on 98 eligible study participants. The blood pressure, National Institute of Health Stroke Scale (NIHSS) score and power of limbs were noted. The data were analysed using one-way Analysis Of Variance (ANOVA) followed by Dunnett’s Multiple Comparison Test.<strong></strong></p><p class="ParaAttribute0"><strong>Results: </strong>Among 150 randomised patients, 110 met the inclusion criteria, and 98 came for follow-up whose data was recorded. Telmisartan showed significant improvement in total NIHSS score compared to amlodipine (P ≤ 0.01) and mannitol (P ≤ 0.01). The mean reduction in SBP and DBP was significant with respect to telmisartan compared to amlodipine (P≤ 0.01). Telmisartan showed significant improvement of power in right upper limb (UL) compared to amlodipine (P ≤ 0.05) and mannitol (P ≤ 0.01). Improvement of power in right lower limb (LL) showed significance with respect to telmisartan compared to mannitol (P ≤ 0.05). Significant improvement of power in left LL was observed in telmisartan compared to mannitol (P ≤ 0.01).<strong></strong></p><p class="ParaAttribute0"><strong>Conclusion: </strong>Blood pressure reduction is an inevitable component of stroke treatment. Anti-hypertensive treatment seems to be highly efficacious in protecting patients against stroke and stroke recurrence, especially on long term basis. Thus, telmisartan provides a viable insight into the stroke prevention strategy and may be prudent to consider as a reasonable add-on therapy.</p>

Sign in / Sign up

Export Citation Format

Share Document